Walden Biosciences Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 22

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 6

Walden Biosciences General Information

Description

Developer of a drug designed to treat kidney diseases such as chronic kidney disease, acute kidney injury, and others. The company specializes in manufacturing medicines for both rare and prevalent forms of kidney disease that target specific cells, enabling patients to get treatment options that target the kidney at the site of drug action.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • One Kendall Square
  • Suite 7101
  • Cambridge, MA 02139
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • One Kendall Square
  • Suite 7101
  • Cambridge, MA 02139
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Walden Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Secondary Transaction - Private Completed Generating Revenue
1. Early Stage VC (Series A) 06-Oct-2020 Completed Generating Revenue
To view Walden Biosciences’s complete valuation and funding history, request access »

Walden Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
To view Walden Biosciences’s complete cap table history, request access »

Walden Biosciences Patents

Walden Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025259719-A1 Method of administering an anti-soluble urokinase plasominogen activator receptor antibody for the treatment of kidney disease Pending 10-Jun-2024
AU-2023339052-A1 Dynamin activators Pending 09-Sep-2022
EP-4583868-A2 Dynamin activators Pending 09-Sep-2022
EP-4583868-A4 Dynamin activators Pending 09-Sep-2022
US-20260070880-A1 Dynamin activators Pending 09-Sep-2022 C07D265/38
To view Walden Biosciences’s complete patent history, request access »

Walden Biosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Walden Biosciences Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
ARCH Venture Partners Venture Capital Minority
ATEM Capital Venture Capital Minority
Eurofarma Ventures Corporate Venture Capital Minority
Mass General Brigham Ventures Venture Capital Minority
Pandect Bioventures Venture Capital Minority
You’re viewing 5 of 6 investors. Get the full list »

Walden Biosciences FAQs

  • When was Walden Biosciences founded?

    Walden Biosciences was founded in 2020.

  • Where is Walden Biosciences headquartered?

    Walden Biosciences is headquartered in Cambridge, MA.

  • What is the size of Walden Biosciences?

    Walden Biosciences has 22 total employees.

  • What industry is Walden Biosciences in?

    Walden Biosciences’s primary industry is Drug Discovery.

  • Is Walden Biosciences a private or public company?

    Walden Biosciences is a Private company.

  • What is Walden Biosciences’s current revenue?

    The current revenue for Walden Biosciences is .

  • How much funding has Walden Biosciences raised over time?

    Walden Biosciences has raised $51M.

  • Who are Walden Biosciences’s investors?

    ARCH Venture Partners, ATEM Capital, Eurofarma Ventures, Mass General Brigham Ventures, and Pandect Bioventures are 5 of 6 investors who have invested in Walden Biosciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process